IRVING, Texas , Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the selection of 15 physician-scientists to participate in its 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum. This competitive two-year program provides early-career oncologists with hands-on training,... Read More

IRVING, Texas , Nov. 17, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will attend the following investor conferences: Wolfe Research's 7th Annual Healthcare Conference: New York City , New York Investor meetings: November 18 Citi's 2025 Global Healthcare Conference: Miami, Florida... Read More

Revenue growth of 113% driven by strong performance in molecular profiling services Raises 2025 revenue guidance to $720 to $730 million , representing year-over-year growth of 75-77% IRVING, Texas , Nov. 5, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended September 30, 2025 . Third Quarter 2025... Read More

IRVING, Texas , Oct. 29, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced collaborative new research identifying TET2 clonal hematopoiesis (CH) as a promising biomarker for improved response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors. The study titled, `TET2-mutant clonal... Read More

IRVING, Texas , Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025 . Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT ( 4:30 p.m. ET ) to discuss the financial results. Conference Call... Read More

IRVING, Texas , Oct. 14, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, will unveil six studies at the European Society for Medical Oncology (ESMO) Congress 2025, in Berlin, Germany from October 17-21, 2025 . These presentations highlight the transformative power of multiomics, a scientific approach that integrates data... Read More

IRVING, Texas , Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek ® . This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies. It... Read More

IRVING, Texas , Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients. The study found... Read More

IRVING, Texas , July 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025 . Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT ( 4:30 p.m. ET ) to discuss the financial results. Conference Call... Read More

Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas , July 22, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published original data in the New England Journal of Medicine independently validating recent findings on tumor-infiltrating clonal hematopoiesis (TI-CH), and... Read More

Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas , July 8, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal,... Read More